Precision Oncology
Starts Here

Explore our advanced testing solutions, enhanced workflow optimizations, and collaborative partnerships to see what’s possible.

Partner With Us

We’re an Established Precision Oncology Leader

Delivering healthcare innovation with real impact, backed by over a decade of relentless research and development—our leadership speaks for itself.1*

Your Complete Testing Partner

From treatment selection to recurrence detection and progression monitoring, our tests provide the insights you need at every stage of the cancer continuum.

GUARDANT360Tissue

Tissue-based molecular profiling with genomic, transcriptomic, and epigenomic insights.2

Learn More
GUARDANT360 Liquid CDx

#1 liquid biopsy with methylation coverage across the genome for enhanced clinical actionability.3-4*†

Learn More
GUARDANTREVEAL

Fast, tissue-free MRD detection and monitoring.5

Learn More
GUARDANT Hereditary Cancer

Easy to order germline testing featuring a comprehensive hereditary cancer panel.

Learn More
Explore Our Tests

Unlock the Full Potential of Precision Oncology

From research to real-world clinical care, InfinityAI enables teams to move with greater confidence and velocity, optimize testing value, improve practice efficiencies, and maximize assets to enable better outcomes for more patients across different disease areas.​

Purpose-Built Artificial Intelligence

Advanced, domain-specific AI, engineered to unlock clinically meaningful insights from complex, multimodal, longitudinal data.​

Unmatched Multimodal Data Foundation

A large high-fidelity real-world data library with exclusive epigenomic and unmatched longitudinal signals.

End-to-End Decision
Enablement

A complete portfolio of modular data and insight solutions that power confident decision-making to optimize testing value and maximize assets.

Discover InfinityAI

Let’s Connect

Contact Guardant Key Accounts to see how partnering with our team can advance care for your patients.

*Non-unique lives covered across Guardant360 Liquid CDx and Guardant360 Tissue, including overlap across tests and payers.​

†Statement “#1 liquid biopsy” applies to Guardant360 Liquid as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey. ​

Important note: Guardant Reveal®, Guardant360® Tissue, and Guardant Hereditary Cancer were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.​​

  1. Guardant Health Data on File. May 12, 2026. Guardant Health, Inc. Redwood City, CA.
  2. Guardant360® Tissue Assay Specifications. 2025. POL-000127. Guardant Health, Inc. Redwood City, CA.
  3. Guardant Health Data on File. Q1 2026 Late-Stage Chart Audit. Guardant Health, Inc. Redwood City, CA.
  4. Clemens K. Buchheit L, Forbes S, Alshurafa H, Das A, Eltoukhy H. Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers. Abstract 6512. Cancer Res. 2026;86(7suppl):6512. doi:org/10.1158/1538-7445.AM2026-6512
  5. Guardant Reveal Assay Specifications. 2025. Guardant Health, Inc. Redwood City, CA.​

    ​